Sherrill B, Amonkar M, Sherif B, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of qol scores with tumor progression status in first-line hr+, her2+ mbc patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the 32nd San Antoniio Breast Cancer Symposium Annual Meeting; December 14, 2009.
Sherrill B, Amonkar MM, Sherif BN, Maltzman J, O'Rourke L, Johnston S. An exploration of the association of Quality-of-Life (QOL) scores with tumor progression status in first line hormone receptor positive, HER2+ Metastatic Breast Cancer (MBC) patients treated with lapatinib plus letrozole or letrozole alone. Poster presented at the Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium; December 2009. San Antonio, TX. [abstract] Cancer Res. 2009 Dec; 69(24 (Suppl)):5106. doi: 10.1158/0008-5472.SABCS-09-5106
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Sherrill B, Sherif BN, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, her2+ metastatic breast cancer. Poster presented at the Cancer Symposium of the American Society of Clinical Oncology; October 10, 2009.
Sherif BN, Sherrill B, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive her2+ metastatic breast cancer: a quality of life analysis. Poster presented at the 2009 ASCO Annual Meeting; June 2, 2009.
Sherrill EH, Sherif BN, Amonkar MM, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, HER2+ metastatic breast cancer (MBC). Poster presented at the ASCO Breast Cancer Symposium; 2009.